KRAS and non-small cell lung carcinoma: In line with the previously observed differential response to BRAF inhibitors of BRAF V600E mutated melanoma and mCRC, the activity of AMG510 in KRAS G12C mutated CRC is substantially lower than in non-small cell lung cancer (NSCLC).